Search

Your search keyword '"Widner H"' showing total 308 results

Search Constraints

Start Over You searched for: Author "Widner H" Remove constraint Author: "Widner H"
308 results on '"Widner H"'

Search Results

6. Clinical characteristics of long-term survivors in multiple system atrophy: An analysis of the EMSA-SG registry: 299

8. PET molecular imaging of phosphodiesterase 10A: An early biomarker of Huntington's disease progression

9. The European Multiple System Atrophy-Study Group (EMSA-SG)

13. Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease

14. Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study

15. Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study

21. Chapter 83 Neural transplantation in Parkinson's disease: the Swedish experience

22. 11C-PE2I and 18F-DOPA PET for assessing progression rate in Parkinson’s: a longitudinal study

23. Suicidal ideation in a European Huntington's disease population

24. A genome-wide association study in multiple system atrophy

25. Increased serotonin-to-dopamine transporter ratios in Parkinson disease dyskinesias: a longitudinal study

26. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross‐sectional study of iron‐related magnetic resonance imaging susceptibility

27. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: An observational cohort study

28. A genome-wide association study in multiple system atrophy

29. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY

30. Mutant COQ2 in multiple-system atrophy

31. Red flags for multiple system atrophy

37. Presentation, diagnosis, and management of multiple system atrophy in Europe:final analysis of the European multiple system atrophy registry

38. ON BEHALF OF THE EMSA‐SG. PRESENTATION, DIAGNOSIS, AND MANAGEMENT OF MULTIPLE SYSTEM ATROPHY IN EUROPE: FINAL ANALYSIS OF THE EUROPEAN MULTIPLE SYSTEM ATROPHY REGISTRY

40. Treatment of end-of-dose wearing-off in Parkinson's disease:Stalevo® (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess®/Comtan® (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment

42. The natural history of multiple system atrophy: a prospective European cohort study

43. Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease

46. Safety and efficacy of recombinant human platelet derived growth factor (Rhpdgf) in Parkinson's disease

49. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease

50. Fifteen months' follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism

Catalog

Books, media, physical & digital resources